Interventions for obstructive uropathy in advanced prostate cancer: a population-based study
Authors
Nathan, A.Morris, M.
Parry, M. G.
Berry, B.
Sujenthiran, A.
Nossiter, J.
Payne, H.
Van Der Meulen, J.
Clarke, Noel W
Green, J. S. A.
Affiliation
Clinical Effectiveness Unit, The Royal College of Surgeons of England, United KingdomIssue Date
2022
Metadata
Show full item recordAbstract
Objectives: Upper tract obstructive uropathy (UTOU) is a complication of advanced prostate cancer (PCa) that may require urinary tract decompression. There are no population-based studies on the incidence, treatment, and outcomes of this complication. We developed and validated a coding framework to identify procedures for UTOU in men with locally advanced and metastatic PCa using administrative hospital data to assess clinical outcomes. Patients and methods: Patients newly diagnosed with PCa between April 2014 and March 2019 were identified in the English cancer registry. A coding framework based on procedure (OPCS-4) and diagnostic (ICD-10) codes was developed and validated. Subsequent clinical outcomes were determined using Hospital Episodes Statistics (HES) to determine the utility of the intervention. Results: A total of 77,010 patients newly diagnosed with locally advanced, and 30,083 patients with metastatic PCa were identified. Of these, 1,951 (1.8%) patients underwent an intervention for UTOU according to our coding framework: 830 (42.5%) had locally advanced disease and 1,121 (57.5%) had metastatic disease. 844 (43.3%) had a percutaneous nephrostomy (PCN), 473 (24.2%) had a PCN with antegrade stent and 634 (32.5%) had a retrograde stent. Mean follow-up time was 43.2 months. The cumulative incidence of the use of these interventions at one, three, and five years was 2.5%, 3.6% and 4.2% in men with metastases compared to 0.5%, 0.9% and 1.4% in men with locally advanced disease. Conclusion: A new coding framework, developed to identify procedures for UTOU. was applied in the largest study to date of UTOU in men with primary locally advanced and metastatic PCa. Results demonstrated that 2% of men with locally advanced PCa and 4% of men with metastatic PCa require an intervention to resolve UTOU within 5 years of their PCa diagnosis.Citation
Nathan A, Morris M, Parry MG, Berry B, Sujenthiran A, Nossiter J, et al. Interventions for obstructive uropathy in advanced prostate cancer: a population‐based study. BJU International. Wiley; 2022.Journal
BJU InternationalDOI
10.1111/bju.15766PubMed ID
35485254Additional Links
https://dx.doi.org/10.1111/bju.15766Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bju.15766
Scopus Count
Collections
Related articles
- Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
- Authors: Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-Antolín A, Villavicencio H, 25 Urology Units, Asociación Española de Urología, Cantalapiedra A, Pedrosa E
- Issue date: 2012 Dec
- Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data.
- Authors: Parry MG, Cowling TE, Sujenthiran A, Nossiter J, Berry B, Cathcart P, Clarke NW, Payne H, Aggarwal A, van der Meulen J
- Issue date: 2019 Dec
- Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
- Authors: Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P
- Issue date: 2011 Sep
- Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
- Authors: Thomsen FB, Mikkelsen MK, Hansen RB, Krug AH, Glenthøj A, Stattin P, Brasso K
- Issue date: 2016 Dec
- Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden.
- Authors: Orrason AW, Westerberg M, Garmo H, Lissbrant IF, Robinson D, Stattin P
- Issue date: 2020 Jul